BACKGROUND Acute Myocardial Infraction (AMI) is a serious and life-threatening manifestation of coronary artery disease (CAD) affecting both males and females, which need immediate management. The present study was aimed to assess the gender difference and factors affecting pre-hospital delay among patients with AMI. MATERIALS AND METHODS The 290 patients admitted with AMI from 13-02-2016 to 26-03-2016 were studied. A descriptive comparative design was adopted for the study. Socio personal and clinical variables of the subjects were assessed. Pre-hospital delay was measured in terms of time from the onset of symptoms till the patient reaches a health care setting. One hour after the onset of symptom of AMI was considered as the Golden hour. Data was analysed using SPSS 20.0 software.
Utilization of α,α-dihalocarbonyl compounds as synthetic equivalents to α-halocarbonyl compounds has been explored in the synthesis of a wide range of highly useful heterocycles and α-functionalized ketones. The continuously growing demand of α,α-dibromoketones, as highly reactive and mild synthetic precursors/intermediates, to carry out selective organic transformations, prompted us to investigate their potential application for the synthesis of thiazolo[3,2-a]benzimidazoles. In this study, a remarkable application of α,α-dibromoacetophenones 5a-g in the development of a facile protocol for the synthesis of thiazolo[3,2-a]benzimidazoles 4a-g by avoiding the use of lachrymatory α-haloketones is described. Although the mechanism for the debromination from the intermediate compound 6 under these conditions is not confirmed, possible pathways have been suggested.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.